Literature DB >> 21257235

Coexistence of narcolepsy and Alzheimer's disease.

T E Scammell1, J K Matheson, M Honda, T C Thannickal, J M Siegel.   

Abstract

A recent publication suggested that hypocretin (Hcrt, orexin) may mediate the neuropathological process leading to Alzheimer's disease (AD) and that antagonism of hypocretin receptors decreases this process. Narcoleptics have an approximately 90% loss of Hcrt neurons and commensurate reductions in the levels of Hcrt in their cerebrospinal fluid beginning at disease onset, usually before the age of 30. If Hcrt mediates the disease process, narcoleptics should be protected against AD. We examined the postmortem neuropathology and clinical records of 12 sequentially encountered cases of human narcolepsy. We found that AD was present in 4 of these narcoleptics, a prevalence that is similar to that of the general population. Published by Elsevier Inc.

Entities:  

Mesh:

Year:  2011        PMID: 21257235      PMCID: PMC8720268          DOI: 10.1016/j.neurobiolaging.2010.12.008

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  9 in total

1.  Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported.

Authors:  D A Evans; H H Funkenstein; M S Albert; P A Scherr; N R Cook; M J Chown; L E Hebert; C H Hennekens; J O Taylor
Journal:  JAMA       Date:  1989-11-10       Impact factor: 56.272

2.  Concomitant loss of dynorphin, NARP, and orexin in narcolepsy.

Authors:  A Crocker; R A España; M Papadopoulou; C B Saper; J Faraco; T Sakurai; M Honda; E Mignot; T E Scammell
Journal:  Neurology       Date:  2005-09-14       Impact factor: 9.910

3.  A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains.

Authors:  C Peyron; J Faraco; W Rogers; B Ripley; S Overeem; Y Charnay; S Nevsimalova; M Aldrich; D Reynolds; R Albin; R Li; M Hungs; M Pedrazzoli; M Padigaru; M Kucherlapati; J Fan; R Maki; G J Lammers; C Bouras; R Kucherlapati; S Nishino; E Mignot
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

4.  Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle.

Authors:  Jae-Eun Kang; Miranda M Lim; Randall J Bateman; James J Lee; Liam P Smyth; John R Cirrito; Nobuhiro Fujiki; Seiji Nishino; David M Holtzman
Journal:  Science       Date:  2009-09-24       Impact factor: 47.728

5.  Alzheimer disease in the US population: prevalence estimates using the 2000 census.

Authors:  Liesi E Hebert; Paul A Scherr; Julia L Bienias; David A Bennett; Denis A Evans
Journal:  Arch Neurol       Date:  2003-08

6.  Absence of ubiquitinated inclusions in hypocretin neurons of patients with narcolepsy.

Authors:  M Honda; T Arai; M Fukazawa; Y Honda; K Tsuchiya; A Salehi; H Akiyama; E Mignot
Journal:  Neurology       Date:  2009-08-18       Impact factor: 9.910

7.  Narp immunostaining of human hypocretin (orexin) neurons: loss in narcolepsy.

Authors:  A M Blouin; T C Thannickal; P F Worley; J M Baraban; I M Reti; J M Siegel
Journal:  Neurology       Date:  2005-08-31       Impact factor: 9.910

8.  Reduced number of hypocretin neurons in human narcolepsy.

Authors:  T C Thannickal; R Y Moore; R Nienhuis; L Ramanathan; S Gulyani; M Aldrich; M Cornford; J M Siegel
Journal:  Neuron       Date:  2000-09       Impact factor: 17.173

9.  Hypocretin (orexin) cell loss in Parkinson's disease.

Authors:  Thomas C Thannickal; Yuan-Yang Lai; Jerome M Siegel
Journal:  Brain       Date:  2007-05-09       Impact factor: 13.501

  9 in total
  12 in total

Review 1.  Sleep: A Novel Mechanistic Pathway, Biomarker, and Treatment Target in the Pathology of Alzheimer's Disease?

Authors:  Bryce A Mander; Joseph R Winer; William J Jagust; Matthew P Walker
Journal:  Trends Neurosci       Date:  2016-06-17       Impact factor: 13.837

2.  Ictal SPECT in patients with rapid eye movement sleep behaviour disorder.

Authors:  Geert Mayer; Marion Bitterlich; Torsten Kuwert; Philipp Ritt; Hermann Stefan
Journal:  Brain       Date:  2015-03-01       Impact factor: 13.501

Review 3.  Sleep disorders, obesity, and aging: the role of orexin.

Authors:  Joshua P Nixon; Vijayakumar Mavanji; Tammy A Butterick; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Ageing Res Rev       Date:  2014-11-22       Impact factor: 10.895

4.  Orexin/hypocretin treatment restores hippocampal-dependent memory in orexin-deficient mice.

Authors:  Vijayakumar Mavanji; Tammy A Butterick; Cayla M Duffy; Joshua P Nixon; Charles J Billington; Catherine M Kotz
Journal:  Neurobiol Learn Mem       Date:  2017-10-28       Impact factor: 2.877

Review 5.  Impact of sleep disturbances on neurodegeneration: Insight from studies in animal models.

Authors:  Jessica E Owen; Sigrid C Veasey
Journal:  Neurobiol Dis       Date:  2020-02-19       Impact factor: 5.996

Review 6.  Interactions of the histamine and hypocretin systems in CNS disorders.

Authors:  Ling Shan; Yves Dauvilliers; Jerome M Siegel
Journal:  Nat Rev Neurol       Date:  2015-06-23       Impact factor: 42.937

Review 7.  Focus on the Complex Interconnection between Cancer, Narcolepsy and Other Neurodegenerative Diseases: A Possible Case of Orexin-Dependent Inverse Comorbidity.

Authors:  Maria P Mogavero; Alessandro Silvani; Lourdes M DelRosso; Michele Salemi; Raffaele Ferri
Journal:  Cancers (Basel)       Date:  2021-05-26       Impact factor: 6.639

8.  Con: Alzheimer's disease and circadian dysfunction: chicken or egg?

Authors:  Abhay Moghekar; Richard J O'Brien
Journal:  Alzheimers Res Ther       Date:  2012-08-13       Impact factor: 6.982

9.  Is suvorexant a better choice than alternative hypnotics?

Authors:  Daniel F Kripke
Journal:  F1000Res       Date:  2015-08-03

Review 10.  Hypocretin (orexin) regulation of sleep-to-wake transitions.

Authors:  Luis de Lecea; Ramón Huerta
Journal:  Front Pharmacol       Date:  2014-02-12       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.